BioCentury | Jun 15, 2009
Clinical News

EN101: Phase IIa data

...for the indication. Amarin Corp. plc (NASDAQ:AMRN), Dublin, Ireland Product: EN101 Business: Autoimmune Molecular target: R isoform of acetylcholinesterase (AChE-R) mRNA...
BioCentury | Jun 15, 2009
Company News

Amarin deal

...$17 million in milestones related to development of EN101. The oral antisense oligonucleotide targeting the R isoform of acetylcholinesterase (AChE-R) mRNA...
BioCentury | Jun 11, 2009
Clinical News

Amarin's EN101 meets Phase IIa endpoint

...p=0.001), 16.8% (p<0.001) and 20.3% (p<0.001), respectively. EN101 is an oral antisense oligonucleotide targeting the R isoform of acetylcholinesterase (AChE-R) mRNA...
Items per page:
1 - 3 of 3